The Daily Buyout
$440MDivestiture / carve-outHealthcare & Life Sciences

Grünenthal to Acquire Bayer's Stivarga for up to €375M

Grünenthal agreed to acquire the oral cancer treatment Stivarga (regorafenib) from Bayer AG for up to €375 million, with closing expected by end of 2026 or early 2027.

Read the full coverage, free

We only link to sources you can read without a subscription. How we check.

More Healthcare & Life Sciences deals